Andrew Mitchell1,1, Sarrah L Hasanali2,1, Daley S Morera2, Rohitha Baskar2, Xin Wang2, Rahil Khan3, Asif Talukder1, Charles S Li2, Meenakkshy Manoharan4, Andre R Jordan2,5, Jiaojiao Wang2, Roni J Bollag3,6, Nagendra Singh2, Daniel Albo1, Santu Ghosh7, Vinata B Lokeshwar2. 1. Department of Surgery, Medical College of Georgia, Augusta University, Augusta, GA, USA. 2. Biochemistry and Molecular Biology, Medical College of Georgia, Augusta University, Augusta, GA, USA. 3. Bio-Repository Alliance of Georgia for Oncology at Georgia Cancer Center, Medical College of Georgia, Augusta University, Augusta, GA, USA. 4. Washington University at St Louis, St Louis, MO, USA. 5. Sheila and David Fuente Graduate Program in Cancer Biology, Sylvester Comprehensive Cancer Center, University of Miami-Miller School of Medicine, Miami, FL, USA. 6. Department of Pathology, Medical College of Georgia, Augusta University, Augusta, GA, USA. 7. Department of Population Health Sciences, Medical College of Georgia, Augusta University, Augusta, GA, USA.
Abstract
BACKGROUND: Differential expression of chemokines/chemokine receptors in colorectal cancer (CRC) may enable molecular characterization of patients' tumors for predicting clinical outcome. OBJECTIVE: To evaluate the prognostic ability of these molecules in a CRC cohort and the CRC TCGA-dataset. METHODS: Chemokine (CXCL-12α, CXCL-12β, IL-17A, CXCL-8, GM-CSF) and chemokine receptor (CXCR-4, CXCR-7) transcripts were analyzed by RT-qPCR in 76 CRC specimens (normal: 27, tumor: 49; clinical cohort). RNA-Seq data was analyzed from the TCGA-dataset (n= 375). Transcript levels were correlated with outcome; analyses: univariate, multivariable, Kaplan-Meier. RESULTS: In the clinical cohort, chemokine/chemokine receptor levels were elevated 3-10-fold in CRC specimens (P⩽ 0.004) and were higher in patients who developed metastasis (P= 0.03 - < 0.0001). CXCR-4, CXCR-7, CXCL-12α, CXCL-8, IL-17 and GM-CSF levels predicted metastasis (P⩽ 0.0421) and/or overall survival (OS; P⩽ 0.0373). The CXCR-4+CXCR-7+CXCL-12 marker (CXCR-4/7+CXCL-12 (α/b) signature) stratified patients into risk for metastasis (P= 0.0014; OR, 2.72) and OS (P= 0.0442; OR, 2.7); sensitivity: 86.67%, specificity: 97.06%. In the TCGA-dataset, the CXCR-4/7+CXCL-12 signature predicted metastasis (P= 0.011; OR, 2.72) and OS (P= 0.0006; OR: 4.04). In both datasets, the signature was an independent predictor of clinical outcome. CONCLUSIONS: Results of 451 specimens from both cohorts reveal that the CXCR-4/7+CXCL-12 signature potentially predicts outcome in CRC patients and may allow earlier intervention.
BACKGROUND: Differential expression of chemokines/chemokine receptors in colorectal cancer (CRC) may enable molecular characterization of patients' tumors for predicting clinical outcome. OBJECTIVE: To evaluate the prognostic ability of these molecules in a CRC cohort and the CRC TCGA-dataset. METHODS: Chemokine (CXCL-12α, CXCL-12β, IL-17A, CXCL-8, GM-CSF) and chemokine receptor (CXCR-4, CXCR-7) transcripts were analyzed by RT-qPCR in 76 CRC specimens (normal: 27, tumor: 49; clinical cohort). RNA-Seq data was analyzed from the TCGA-dataset (n= 375). Transcript levels were correlated with outcome; analyses: univariate, multivariable, Kaplan-Meier. RESULTS: In the clinical cohort, chemokine/chemokine receptor levels were elevated 3-10-fold in CRC specimens (P⩽ 0.004) and were higher in patients who developed metastasis (P= 0.03 - < 0.0001). CXCR-4, CXCR-7, CXCL-12α, CXCL-8, IL-17 and GM-CSF levels predicted metastasis (P⩽ 0.0421) and/or overall survival (OS; P⩽ 0.0373). The CXCR-4+CXCR-7+CXCL-12 marker (CXCR-4/7+CXCL-12 (α/b) signature) stratified patients into risk for metastasis (P= 0.0014; OR, 2.72) and OS (P= 0.0442; OR, 2.7); sensitivity: 86.67%, specificity: 97.06%. In the TCGA-dataset, the CXCR-4/7+CXCL-12 signature predicted metastasis (P= 0.011; OR, 2.72) and OS (P= 0.0006; OR: 4.04). In both datasets, the signature was an independent predictor of clinical outcome. CONCLUSIONS: Results of 451 specimens from both cohorts reveal that the CXCR-4/7+CXCL-12 signature potentially predicts outcome in CRC patients and may allow earlier intervention.
Entities:
Keywords:
CXCL-12; CXCL-8; CXCR-4; CXCR-7; colorectal cancer
Authors: Kathrin Rupertus; Janine Sinistra; Claudia Scheuer; Ruth M Nickels; Martin K Schilling; Michael D Menger; Otto Kollmar Journal: Clin Exp Metastasis Date: 2014-02-04 Impact factor: 5.150
Authors: Yoon Ji Choi; Won Jin Chang; Sang Won Shin; Kyong Hwa Park; Seung Tae Kim; Yeul Hong Kim Journal: Onco Targets Ther Date: 2016-06-01 Impact factor: 4.147
Authors: Andre R Jordan; Jiaojiao Wang; Travis J Yates; Sarrah L Hasanali; Soum D Lokeshwar; Daley S Morera; Nagarajarao Shamaladevi; Charles S Li; Zachary Klaassen; Martha K Terris; Muthusamy Thangaraju; Amar B Singh; Mark S Soloway; Vinata B Lokeshwar Journal: Oncogenesis Date: 2020-05-19 Impact factor: 7.485